Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the HSG 2022 Annual Meeting; November 2022. Tampa, FL. [abstract] J Huntingtons Dis. 2022 Oct 31; 11(s1):S31. Previously presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting. doi: 10.3233/JHD-229005
Connor MJ, Khoo V, Watson V, Ahmed HU. Radical treatment without cure: decision-making in oligometastatic prostate cancer. Eur Urol. 2021 Apr;79(4):558-60. doi: 10.1016/j.eururo.2021.01.029
Wolowacz SE, Petrillo J, Doward LC, Briggs A. Measuring health-state utility values in clinical trials: can we do better? Ispor Connections. 2014 Sep;20(5):4-8.
Stull DE, Houghton KF, Petrillo J. Innovative data analysis for demonstrating product value: analysis of heterogeneity in treatment response in clinical trials. Ispor Connections. 2013;19(1):5-8.
Masters E, Zlateva G, Harris NI. Real-world data for use in the real world: the pain paradigm. Ispor Connections. 2013;19(2):9-11.
Wolowacz SE, Khan SB. The New National Institute of Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) process: experience from the first completed appraisals. Ispor Connections. 2007;13(2):12-5.
DiBenedetti DB, Gondek K, Sagnier PP, Kubin M, Keininger D, Marquis P. The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners. Eur Urol. 2005 Sep 1;48(3):503-11.
Overland GB, Vatten L, Rhodes T, DeMuro C, Jacobsen G, Vada K, Angelsen A, Girman CJ. Lower urinary tract symptoms, prostate volume and uroflow in Norwegian community men. Eur Urol. 2001 Jan 1;39(1):36-41.
Mansfield CA. A consistent method for calibrating contingent value survey data. South Econ J. 1998;64(3):665-81.